Overview

Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).

Status:
Recruiting
Trial end date:
2031-12-23
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate long-term safety and tolerability of ianalumab in participants with systemic lupus erythematosus who have previously completed the treatment period in one of the two SIRIUS-SLE core studies (CVAY736F12301 or CVAY736F12302).
Phase:
Phase 3
Details
Lead Sponsor:
Novartis Pharmaceuticals